Tech

CDC releases clinical guidance on e-cigarette lung injury

In an early-release Oct. 11 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, the CDC presents interim guidance to help clinicians assess, evaluate, manage, and follow patients with electronic cigarette, or vaping, product use-associated lung injury (EVALI).

David A. Siegel, M.D., from the CDC in Atlanta, and colleagues assessed national surveillance data regarding clinical features of recently reported cases of EVALI. The authors then updated interim recommendations based on these data for U.S. health care providers caring for patients with suspected or known EVALI.

The interim guidance recommends that health care providers evaluating patients suspected to have EVALI ask about the use of e-cigarette, or vaping, products in “a nonjudgmental and thorough manner.” Patients suspected of having EVALI should have a chest radiograph. Hospital admission is recommended for patients with decreased blood oxygen saturation (<95 percent) on room air or who are in respiratory distress. Empiric use of a combination of antibiotics, antivirals, or steroids should be considered based on clinical context. To help patients discontinue use of e-cigarette, or vaping, products, evidence-based tobacco product cessation strategies are recommended. Patients who have been treated for EVALI should not use e-cigarette, or vaping, products to reduce the risk for recurrence.

“Rapid recognition by health care providers of patients with EVALI and an increased understanding of treatment considerations could reduce morbidity and mortality associated with this injury,” the authors write.

Source: www.medicalxpress.com

Related posts

Soom launches mobile app that alerts patients, providers of medical device recalls

Bodyelectron.com

AliveCor stops selling KardiaBand, its ECG accessory for Apple Watches

Bodyelectron.com

Computer program predicts risk of deadly irregular heart beats

Bodyelectron.com